TriSalus Life Sciences, Inc. (TLSI)
| Market Cap | 254.30M-14.8% |
| Revenue (ttm) | 45.08M |
| Net Income | -57.25M |
| EPS | -1.22 |
| Shares Out | 61.57M |
| PE Ratio | n/a |
| Forward PE | -16.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,814 |
| Open | 4.13 |
| Previous Close | 4.25 |
| Day's Range | 4.13 - 4.13 |
| 52-Week Range | 2.20 - 7.95 |
| Beta | 0.47 |
| Analysts | none |
| Price Target | 10.40(+151.82%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About TLSI
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TLSI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TLSI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TLSI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TLSI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TLSI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TLSI from public contracts
Source: USAspending.gov
TLSI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TLSI’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score